Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients

A 5-year prospective study

Kari Britt Hagen, Turid Aas, Jan Terje Kvaløy, Havard Soiland, Ragna Lind

Research output: Contribution to journalArticle

Abstract

Purpose: Adjuvant endocrine therapy (ET) in breast cancer reduces recurrence risk and increases overall survival. The aim of the study was to quantify non-adherence and discontinuation to ET in postmenopausal women with breast cancer, and identify possible clinical or social risk factors. Methods: Women with hormone-receptor positive breast cancer (N = 138), mean age 58 (SD 9.3) years, filled in 4 questionnaires within 1–12, 24, 36 and 48–60 months after surgery; Subjective Health Complaints Inventory (SHC), Functional Assessment of Cancer Therapy-Social Support Subscale (FACT-ES), and Quality of Patient Information Questionnaire (QPI). Adherence to Tamoxifen (Tam) or Aromatase Inhibitors (AI) was examined using the self-reported Morisky Medication Adherence Scale (MMAS-8) and data from the Norwegian Prescription Database (NorPD). Kaplan-Meier curves and Cox proportional hazards regression models estimated adherence to ET. Results: The estimate of discontinued ET within 60 months was 38%. Self-reported discontinuation was 7% compared with 25% from the NorPD. Being overweight or obese were significantly time dependent factors predictive for discontinuing ET, p = 0.025. Conclusion: Closer follow-ups, tailor-made information about the proven benefits of ET, and keeping a normal body mass index (BMI) may improve adherence to ET in postmenopausal women with breast cancer.

Original languageEnglish (US)
Pages (from-to)52-58
Number of pages7
JournalBreast
Volume44
DOIs
StatePublished - Apr 1 2019

Fingerprint

Prospective Studies
Breast Neoplasms
Therapeutics
Prescriptions
Databases
Diagnostic Self Evaluation
Aromatase Inhibitors
Medication Adherence
Tamoxifen
Proportional Hazards Models
Social Support
Body Mass Index
Hormones
Recurrence
Equipment and Supplies
Survival
Neoplasms
Surveys and Questionnaires

Keywords

  • Adherence
  • Adjuvant endocrine therapy
  • Body mass index
  • Breast cancer
  • Self-reported health complaints

ASJC Scopus subject areas

  • Surgery

Cite this

Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients : A 5-year prospective study. / Hagen, Kari Britt; Aas, Turid; Kvaløy, Jan Terje; Soiland, Havard; Lind, Ragna.

In: Breast, Vol. 44, 01.04.2019, p. 52-58.

Research output: Contribution to journalArticle

Hagen, Kari Britt ; Aas, Turid ; Kvaløy, Jan Terje ; Soiland, Havard ; Lind, Ragna. / Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients : A 5-year prospective study. In: Breast. 2019 ; Vol. 44. pp. 52-58.
@article{4d5c88703946418399c1d458e007110f,
title = "Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study",
abstract = "Purpose: Adjuvant endocrine therapy (ET) in breast cancer reduces recurrence risk and increases overall survival. The aim of the study was to quantify non-adherence and discontinuation to ET in postmenopausal women with breast cancer, and identify possible clinical or social risk factors. Methods: Women with hormone-receptor positive breast cancer (N = 138), mean age 58 (SD 9.3) years, filled in 4 questionnaires within 1–12, 24, 36 and 48–60 months after surgery; Subjective Health Complaints Inventory (SHC), Functional Assessment of Cancer Therapy-Social Support Subscale (FACT-ES), and Quality of Patient Information Questionnaire (QPI). Adherence to Tamoxifen (Tam) or Aromatase Inhibitors (AI) was examined using the self-reported Morisky Medication Adherence Scale (MMAS-8) and data from the Norwegian Prescription Database (NorPD). Kaplan-Meier curves and Cox proportional hazards regression models estimated adherence to ET. Results: The estimate of discontinued ET within 60 months was 38{\%}. Self-reported discontinuation was 7{\%} compared with 25{\%} from the NorPD. Being overweight or obese were significantly time dependent factors predictive for discontinuing ET, p = 0.025. Conclusion: Closer follow-ups, tailor-made information about the proven benefits of ET, and keeping a normal body mass index (BMI) may improve adherence to ET in postmenopausal women with breast cancer.",
keywords = "Adherence, Adjuvant endocrine therapy, Body mass index, Breast cancer, Self-reported health complaints",
author = "Hagen, {Kari Britt} and Turid Aas and Kval{\o}y, {Jan Terje} and Havard Soiland and Ragna Lind",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.breast.2019.01.003",
language = "English (US)",
volume = "44",
pages = "52--58",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients

T2 - A 5-year prospective study

AU - Hagen, Kari Britt

AU - Aas, Turid

AU - Kvaløy, Jan Terje

AU - Soiland, Havard

AU - Lind, Ragna

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose: Adjuvant endocrine therapy (ET) in breast cancer reduces recurrence risk and increases overall survival. The aim of the study was to quantify non-adherence and discontinuation to ET in postmenopausal women with breast cancer, and identify possible clinical or social risk factors. Methods: Women with hormone-receptor positive breast cancer (N = 138), mean age 58 (SD 9.3) years, filled in 4 questionnaires within 1–12, 24, 36 and 48–60 months after surgery; Subjective Health Complaints Inventory (SHC), Functional Assessment of Cancer Therapy-Social Support Subscale (FACT-ES), and Quality of Patient Information Questionnaire (QPI). Adherence to Tamoxifen (Tam) or Aromatase Inhibitors (AI) was examined using the self-reported Morisky Medication Adherence Scale (MMAS-8) and data from the Norwegian Prescription Database (NorPD). Kaplan-Meier curves and Cox proportional hazards regression models estimated adherence to ET. Results: The estimate of discontinued ET within 60 months was 38%. Self-reported discontinuation was 7% compared with 25% from the NorPD. Being overweight or obese were significantly time dependent factors predictive for discontinuing ET, p = 0.025. Conclusion: Closer follow-ups, tailor-made information about the proven benefits of ET, and keeping a normal body mass index (BMI) may improve adherence to ET in postmenopausal women with breast cancer.

AB - Purpose: Adjuvant endocrine therapy (ET) in breast cancer reduces recurrence risk and increases overall survival. The aim of the study was to quantify non-adherence and discontinuation to ET in postmenopausal women with breast cancer, and identify possible clinical or social risk factors. Methods: Women with hormone-receptor positive breast cancer (N = 138), mean age 58 (SD 9.3) years, filled in 4 questionnaires within 1–12, 24, 36 and 48–60 months after surgery; Subjective Health Complaints Inventory (SHC), Functional Assessment of Cancer Therapy-Social Support Subscale (FACT-ES), and Quality of Patient Information Questionnaire (QPI). Adherence to Tamoxifen (Tam) or Aromatase Inhibitors (AI) was examined using the self-reported Morisky Medication Adherence Scale (MMAS-8) and data from the Norwegian Prescription Database (NorPD). Kaplan-Meier curves and Cox proportional hazards regression models estimated adherence to ET. Results: The estimate of discontinued ET within 60 months was 38%. Self-reported discontinuation was 7% compared with 25% from the NorPD. Being overweight or obese were significantly time dependent factors predictive for discontinuing ET, p = 0.025. Conclusion: Closer follow-ups, tailor-made information about the proven benefits of ET, and keeping a normal body mass index (BMI) may improve adherence to ET in postmenopausal women with breast cancer.

KW - Adherence

KW - Adjuvant endocrine therapy

KW - Body mass index

KW - Breast cancer

KW - Self-reported health complaints

UR - http://www.scopus.com/inward/record.url?scp=85060335870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060335870&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2019.01.003

DO - 10.1016/j.breast.2019.01.003

M3 - Article

VL - 44

SP - 52

EP - 58

JO - Breast

JF - Breast

SN - 0960-9776

ER -